Research programme: neuroprotective therapies - ReNeuron
Latest Information Update: 12 Apr 2007
At a glance
- Originator ReNeuron
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuroprotection
Most Recent Events
- 28 Feb 2002 Preclinical trials in Neuroprotection in USA (unspecified route)